Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer
Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug Administration (FDA) for the treatment of another ... Read More
Olema Oncology raises $54m for breast cancer drug candidate OP-1250
Olema Oncology, a California-based biopharma company focused on developing targeted therapies for women's cancers, has raised $54 million in a Series B financing round, which ... Read More
Pharma giants bag Lynparza EMA approval for metastatic breast cancer
Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency's (EMA) approval for their poly ADP-ribose polymerase ... Read More
Genentech gets Kadcyla FDA approval for post-surgery treatment of HER2+ EBC
Kadcyla FDA approval : Roche subsidiary Genentech has secured approval from the US Food and Drug Administration (FDA) for its breast cancer drug Kadcyla (ado-trastuzumab ... Read More
Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men
New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover ... Read More
FDA approves Eli Lilly’s Verzenio for metastatic breast cancer treatment
Eli Lilly and Company (Lilly) has announced receiving U.S. Food and Drug Administration (FDA) approval for Verzenio (abemaciclib), to treat patients with metastatic breast cancer ... Read More
Lilly’s breast cancer drug abemaciclib shows promising results in phase 3 trial
Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its innovative breast cancer treatment, abemaciclib, in combination ... Read More